Now approved from 2 years of age
Precision Medicine
Target the root, restore the balance
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
In just five minutes, see how early intervention with IMCIVREE helped transform a 4-year-old’s life – Dr. Mónica Ruiz shares a real life patient story!
Explore the VENTURE trial findings
The VENTURE trial demonstrates the importance of intervening early to improve outcomes for patients aged 2—<6 with BBS or with LEPR or POMC deficiency.1
*BBS , Bardet-Biedl syndrome; LEPR , leptin receptor; POMC, proopiomelanocortin.
Request an IMCIVREE information session
Our colleagues can schedule a visit to answer any questions, share more information and provide additional resources
- Get the latest news
- Additional educational materials
- Early awareness of events
- Content for patient support
References:
- 1. Argente J, et al. Lancet Diabetes Endocrinol. 2024;13(1):29–37.